Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Natural products

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44340   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    130 result(s) found for: Natural products. Displaying page 4 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2013-004728-13 Sponsor Protocol Number: I3Y-MC-JPBL Start Date*: 2014-07-09
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without LY2835219, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced ...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DE (Completed) FI (Completed) GR (Trial now transitioned) RO (Ongoing) DK (Completed) PL (Trial now transitioned) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003439-18 Sponsor Protocol Number: D0810C00019 Start Date*: 2009-02-20
    Sponsor Name:AstraZeneca AB
    Full Title: Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or mor...
    Medical condition: platinum sensitive serous ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) PL (Completed) CZ (Completed) ES (Completed) EE (Completed) FR (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005817-23 Sponsor Protocol Number: 8245-005 Start Date*: 2008-12-24
    Sponsor Name:Merck & Co., Inc
    Full Title: A Phase IIA, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-8245 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002600-40 Sponsor Protocol Number: SCY-078-304 Start Date*: 2020-01-17
    Sponsor Name:SCYNEXIS, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects with Recurrent Vulvova...
    Medical condition: Recurrent Vulvovaginal Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-002667-34 Sponsor Protocol Number: WA39085 Start Date*: 2020-03-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLE...
    Medical condition: Relapsing-remitting multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003425-30 Sponsor Protocol Number: EPX-100-001 Start Date*: 2022-07-27
    Sponsor Name:Epygenix Therapeutics, Inc.
    Full Title: A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole HCl) as Adjunctive Therapy in Patients with Dravet Syndrome (ARGUS trial)
    Medical condition: Dravet Syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) HU (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005186-18 Sponsor Protocol Number: S187.3.004 Start Date*: 2007-11-16
    Sponsor Name:Solvay Pharmaceuticals B.V.
    Full Title: Open-Label, 6-12 Months Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations
    Medical condition: Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PT (Completed) IT (Completed) CZ (Completed) ES (Completed) NL (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012076-26 Sponsor Protocol Number: 20080560 Start Date*: 2009-10-01
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivati...
    Medical condition: Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy (ADT) for Non-metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10065687 Bone loss LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) CZ (Completed) PL (Completed) LV (Completed) GR (Completed) SK (Completed) BG (Completed) HU (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2010-024260-17 Sponsor Protocol Number: P08034 Start Date*: 2012-11-08
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) NO (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002389-62 Sponsor Protocol Number: 8-55-52030-309 Start Date*: 2015-03-02
    Sponsor Name:Ipsen Group
    Full Title: Phase IIa, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and pharmacodynamics of a single dose of lanreotide PRF in subjects wi...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) NL (Completed) CZ (Completed) LT (Completed) ES (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005686-20 Sponsor Protocol Number: 004 Start Date*: 2012-08-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients ...
    Medical condition: Patients with Complicated Intra-Abdominal Infection
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) PT (Completed) GR (Completed) LT (Completed) LV (Completed) EE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-001361-32 Sponsor Protocol Number: 14571A Start Date*: 2013-04-29
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of brexpiprazole (1 and 3 mg/day) as adjunctive treatment in el...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004873 10025461 Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behavior LLT
    16.1 100000004873 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    16.1 100000004873 10025457 Major depressive disorder, recurrent episode, mild degree LLT
    16.1 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) LT (Prematurely Ended) FI (Prematurely Ended) SK (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004142-11 Sponsor Protocol Number: A011-11 Start Date*: 2021-05-12
    Sponsor Name:Acceleron Pharma Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed) BE (Completed) NL (Completed) AT (Completed) PL (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001618-27 Sponsor Protocol Number: EMN14/54767414MMY3013 Start Date*: 2017-05-19
    Sponsor Name:Stichting European Myeloma Network (EMN)
    Full Title: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy Wi...
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Ongoing) BE (Completed) DE (Completed) CZ (Completed) DK (Completed) FR (Completed) NL (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002563-27 Sponsor Protocol Number: 12023A Start Date*: 2008-11-24
    Sponsor Name:H. Lundbeck A/S
    Full Title: Nalmefene Efficacy Study II: Randomised, double-blind, placebo-controlled, parallel-group, efficacy study of 20 mg nalmefene, as needed use, in patients with alcohol dependence
    Medical condition: Alcohol dependence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001594 Alcohol dependence syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) ES (Completed) IT (Completed) BE (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-002659-41 Sponsor Protocol Number: MOR208C201 Start Date*: 2012-12-17
    Sponsor Name:MorphoSys AG
    Full Title: A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma
    Medical condition: Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) HU (Completed) ES (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000515-41 Sponsor Protocol Number: A5481044 Start Date*: 2015-11-09
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/META...
    Medical condition: RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063569 Metastatic squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) ES (Completed) PL (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001246-21 Sponsor Protocol Number: CLMF237A2309 Start Date*: 2008-11-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, double-blind, randomized study to compare the efficacy of 24 weeks treatment with fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) versus metformin monotherap...
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000333-31 Sponsor Protocol Number: PQGrass205 Start Date*: 2017-09-13
    Sponsor Name:Allergy Therapeutics (UK) Ltd.
    Full Title: A multi-centre, randomised, double blind, placebo controlled study to determine the optimal effective and safe dose of Pollinex Quattro Grass 1.0 mL (Allergy Therapeutics, (UK) Ltd.) for the treatm...
    Medical condition: Grass pollen-induced seasonal allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019066-92 Sponsor Protocol Number: 2-55-52030-730/TR321 Start Date*: 2010-08-31
    Sponsor Name:Ipsen Pharma SAS
    Full Title: A double-blind, randomized placebo-controlled clinical trial investigating the efficacy and safety of Somatuline Depot (lanreotide) Injection in the treatment of carcinoid syndrome
    Medical condition: Carcinoid syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10007270 Carcinoid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LV (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 03 00:24:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA